Fallopian tube clear cell adenocarcinoma
MONDO:0003383A rare adenocarcinoma of the fallopian tube composed of malignant glandular epithelium containing clear cells.
Also known as: clear cell adenocarcinoma of fallopian tube, clear cell adenocarcinoma of the fallopian tube, clear cell carcinoma of fallopian tube, clear cell carcinoma of the fallopian tube, fallopian tube clear cell adenocarcinoma, fallopian tube clear cell carcinoma
2856 clinical trials for this condition and its sub-types, 18 tagged with Fallopian tube clear cell adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Less invasive surgery may improve recovery for ovarian cancer patients
Disease control Recruiting nowThis study compares two surgical approaches for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have received chemotherapy before surgery. One group will have minimally invasive surgery (small incisions), and the other will have standard open surger…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …
Phase 2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New vaccine aims to outsmart ovarian cancer recurrence
Disease control Recruiting nowThis phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC